News
DVA
199.74
+3.72%
7.16
How Investors Are Reacting To DaVita (DVA) Q1 Earnings Beat And Aggressive Share Buybacks
Simply Wall St · 17h ago
Noteworthy Friday Option Activity: DVA, NKE, OXY
NASDAQ · 1d ago
Companies Have a New AI Problem: Too Many Agents
The Wall Street Journal · 1d ago
DaVita CFO & Treasurer Joel Ackerman Sells 34% Of Holding
Simply Wall St · 2d ago
Best Growth Stocks to Buy for May 14th
NASDAQ · 2d ago
Top DaVita Executive Makes Major Multi-Million Stock Move
TipRanks · 3d ago
Sohn’s rising hedge fund stars pitch stocks at conference, BI reports
TipRanks · 3d ago
Top Stock Picks for Week of May 11, 2026
NASDAQ · 4d ago
Best Growth Stocks to Buy for May 12th
NASDAQ · 4d ago
Top DaVita Executive Makes a Bold Multi-Million Dollar Move
TipRanks · 5d ago
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
NASDAQ · 5d ago
DaVita Is Maintained at Hold by TD Cowen
Dow Jones · 5d ago
TD Cowen Maintains Hold on DaVita, Raises Price Target to $201
Benzinga · 5d ago
Goldman Sachs identifies the S&P 500's most committed share repurchasers
Seeking Alpha · 5d ago
DaVita price target raised to $201 from $144 at TD Cowen
TipRanks · 5d ago
Weekly Report: what happened at DVA last week (0504-0508)?
Weekly Report · 5d ago
Stock index futures fall as hopes of a U.S.-Iran resolution fade
Seeking Alpha · 5d ago
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and DaVita (DVA)
TipRanks · 6d ago
1 Unpopular Stock That Deserves a Second Chance and 2 That Underwhelm
Barchart · 6d ago
Notable healthcare headlines for the week: UnitedHealth, Pfizer, and CVS Health in focus
Seeking Alpha · 6d ago
More
Webull provides a variety of real-time DVA stock news. You can receive the latest news about Davita Inc through multiple platforms. This information may help you make smarter investment decisions.
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.